Investigating Specific Gait Patterns in Individuals Living With Multiple Sclerosis (GAIT-MS)

The study aims to investigate specific ambulation patterns characteristic of the quality of gait in people with MS (pwMS)

Study Overview

• Status: Recruiting
• Conditions: Multiple Sclerosis; Healthy Adult

• Study Type: Observational
• Enrollment (Estimated): 30

Contacts and Locations

• Study Contact: Name: Ferial Toumi; Phone Number: +33 2 78 00 10 98; Email: ferial.toumi@sysnav.fr

Study Locations

• France
  • Lille, France
    • Recruiting
    • CHU Lille
    • Principal Investigator: Patrick Vermersch
    • Contact: Sophie Corbinau; Phone Number: 30768 +33 (0)3.20.44.59.62; Email: sophie.corbinau@chu-lille.fr

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

• Sampling Method: Non-Probability Sample

Study Population

Patients with MS will be recruited from the CHU Lille. Patients will be informed of this study by the Investigator during routine follow-up visits.

The Investigator will also connect with local patient organizations and share a flyer. This flyer will also be displayed within the Neurology and Neurological Rehabilitation departments of the hospital and diffused to the hospital staff.

Description

Inclusion Criteria:

For people living with multiple sclerosis (pwMS):

1. Age at inclusion between =18 and =65 years old
2. Signed informed consent and ability to comply with study and follow-up.
3. Confirmed MS diagnosis according to McDonald criteria (2017)
4. Expanded Disability Status Scale EDSS = 6
5. Stable treatment for 2 months before inclusion (for both disease modifying and symptomatic therapies)
6. Ability and willingness to participate in and comply with all study procedures defined in the protocol
7. Subject will be eligible for enrollment in this study only if either affiliated to, or a beneficiary of a social security category

For Healthy volunteers :

1. Age at inclusion between =18 and =65 years old
2. Signed informed consent and ability to comply with study and follow-up.
3. Ability and willingness to participate in and comply with all study procedures defined in the protocol
4. Subject will be eligible for enrollment in this study only if either affiliated to, or a beneficiary of a social security category

Exclusion Criteria:

For pwMS:

1. Participants with a relapse within the past 3 months before the inclusion
2. Participants with significant cognitive disorders, limiting the understanding of the exercises to be performed or presence of apparent communication difficulties hindering the correct collection of data, as assessed by the investigator
3. Past or present pathology other than MS or surgery or trauma impacting gait, ambulatory function or upper limb function, as assessed by the investigator
4. Vulnerable adults: individuals subject to a legal protection measure (guardianship, limited guardianship, or judicial protection) or unable to express their consent.

For healthy volunteers (HV):

1. Participants with significant cognitive disorders, limiting the understanding of the exercises to be performed or presence of apparent communication difficulties hindering the correct collection of data, as assessed by the investigator
2. Past or present pathology or surgery or trauma impacting gait, ambulatory function or upper limb function, as assessed by the investigator
3. Vulnerable adults: individuals subject to a legal protection measure (guardianship, limited guardianship, or judicial protection) or unable to express their consent.

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort
people living with Multiple Sclerosis
Healthy Adult

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
description of ambulation pattern in controlled environment in people living with multiple sclerosis (pwMS) with different disease severities	Measurement of daily life-like activity movements by Optical Motion Capture, pressure sensitive walkway and wearable sensors	enrollment

Collaborators and Investigators

• Sponsor: SYSNAV
• Investigators: Principal Investigator: Patrick Vermersch, CHU Lille

Study record dates

Study Major Dates

• Study Start (Actual): March 16, 2026
• Primary Completion (Estimated): June 1, 2026
• Study Completion (Estimated): June 1, 2026

Study Registration Dates

• First Submitted: January 28, 2026
• First Submitted That Met QC Criteria: January 28, 2026
• First Posted (Actual): February 5, 2026

Study Record Updates

• Last Update Posted (Actual): March 23, 2026
• Last Update Submitted That Met QC Criteria: March 20, 2026
• Last Verified: March 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Nervous System Diseases; Autoimmune Diseases; Immune System Diseases; Demyelinating Autoimmune Diseases, CNS; Autoimmune Diseases of the Nervous System; Demyelinating Diseases; Multiple Sclerosis
• Other Study ID Numbers: PR5030-119; 2025-A02511-48 (Other Identifier: ANSM)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No